Boston, United States
Kelonia Therapeutics is a biotechnology startup that is revolutionizing in vivo gene delivery to usher in a new era of genetic medicines. Founded in 2017 and headquartered in the United States, Kelonia is pioneering a new wave of genetic medicines using its next generation gene delivery platform. The company’s simple and elegant cutting-edge in vivo gene delivery technology uses a few potent lentiviral vector-like particles to precisely and efficiently deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time.
With an initial focus on developing transformational therapies for solid tumors and hematologic cancers, Kelonia is building a pipeline of genetic medicines for a wide range of diseases, with the bold goal of bringing genetic medicines to every patient in need. The company recently secured a significant $50.00M Series A investment at 28 April 2022 from prominent investors including Venrock, Alta Partners, and Horizons Ventures.
Kelonia's innovative approach to in vivo gene delivery holds the potential to address significant unmet medical needs and advance the field of genetic medicines. The recent investment indicates a strong belief in the company's technology and vision, positioning Kelonia Therapeutics as a promising player in the biotechnology and healthcare industries.
Poseida Therapeutics, Inc.